Literature DB >> 27251880

Application of vancomycin in patients with varying renal function, especially those with augmented renal clearance.

Yang Chu1,2, Yifan Luo1,2, Lianyue Qu1,2, Chunyang Zhao1,2, Mingyan Jiang1.   

Abstract

CONTEXT: Augmented renal clearance (ARC) refers to enhanced renal elimination of circulating solute, and has attracted wide attention in recent years.
OBJECTIVE: This study evaluates the effects of ARC on serum vancomycin concentration in patients administered vancomycin.
MATERIALS AND METHODS: This was a retrospective study in patients receiving vancomycin treatment at a dose of 1000 mg in every 12 h and undergoing serum monitoring admitted over a 2-year period (May 2013 to May 2015), in order to estimate the influence of ARC on serum vancomycin concentration. In this study, statistical comparisons were made on the results from patients grouped according to creatinine clearance (CLcr).
RESULTS: One hundred forty-eight patients were enrolled in our study. The results showed that ARC patients were significantly younger, with a significantly lower Scr and higher GFR. The CLcr and steady-state trough concentrations of serum vancomycin exhibited a logarithmic correlation (Rs = -0.699, R2 = 0.488, p < 0.01) in the patients included in our study. The trough vancomycin concentrations of 62.9% patients in high CLcr group were under 10 μg/mL. DISCUSSION AND
CONCLUSION: Since ARC was significantly associated with subtherapeutic serum vancomycin concentration, it was necessary to devise adjusted dosage regimens for these patients based on their CLcr.

Entities:  

Keywords:  ARC; creatinine clearance; dosage regimen; steady-state trough concentration; therapeutic drug monitoring

Mesh:

Substances:

Year:  2016        PMID: 27251880     DOI: 10.1080/13880209.2016.1183684

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  13 in total

1.  Clinical Pharmacokinetics of Vancomycin in Critically Ill Children.

Authors:  Kannan Sridharan; Amal Al Daylami; Reema Ajjawi; Husain Al-Ajooz; Sindhan Veeramuthu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

Review 2.  Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance.

Authors:  Fatma Hefny; Sukhvir Sambhi; Cassidy Morris; Janice Y Kung; Anna Stuart; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-06-28       Impact factor: 2.569

3.  Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Authors:  Kui-Fen Ma; Yi-Xi Liu; Zheng Jiao; Jun-Hao Lv; Ping Yang; Jian-Yong Wu; Si Yang
Journal:  Front Pharmacol       Date:  2020-10-06       Impact factor: 5.810

4.  Predictive performance of reported vancomycin population pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance.

Authors:  Yan-Xia Yu; Jian Lu; Hao-di Lu; Lan Li; Jing-Jing Li; Lu Shi; Lu-Fen Duan; Zhi-Wei Zhuang; Su-Dong Xue; Yi Shen; Lian Tang
Journal:  Eur J Hosp Pharm       Date:  2021-01-07

Review 5.  Augmented Renal Clearance in Critical Illness: An Important Consideration in Drug Dosing.

Authors:  Sherif Hanafy Mahmoud; Chen Shen
Journal:  Pharmaceutics       Date:  2017-09-16       Impact factor: 6.321

6.  Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.

Authors:  Joaquim F Monteiro; Siomara R Hahn; Jorge Gonçalves; Paula Fresco
Journal:  Pharmacol Res Perspect       Date:  2018-07

7.  Outcomes in patients with infections and augmented renal clearance: A multicenter retrospective study.

Authors:  Yasumasa Kawano; Junichi Maruyama; Ryo Hokama; Megumi Koie; Ryotaro Nagashima; Kota Hoshino; Kentaro Muranishi; Maiko Nakashio; Takeshi Nishida; Hiroyasu Ishikura
Journal:  PLoS One       Date:  2018-12-10       Impact factor: 3.240

8.  Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance.

Authors:  Cui-Yao He; Pan-Pan Ye; Bin Liu; Lin Song; John van den Anker; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

9.  A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment.

Authors:  Lian Tang; Xin-Yuan Ding; Lu-Fen Duan; Lan Li; Hao-di Lu; Feng Zhou; Lu Shi; Jian Lu; Yi Shen; Zhi-Wei Zhuang; Jian-Tong Sun; Qin Zhou; Chen-Qi Zhu; Jing-Jing Li; Yan-Xia Yu
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

10.  Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.

Authors:  Andrew F Shorr; Christopher J Bruno; Zufei Zhang; Erin Jensen; Wei Gao; Hwa-Ping Feng; Jennifer A Huntington; Brian Yu; Elizabeth G Rhee; Carisa De Anda; Sumit Basu; Marin H Kollef
Journal:  Crit Care       Date:  2021-10-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.